Antibodies that inhibit fusion of human immunodeficiency virus-infected cells bind a 24-amino acid sequence of the viral envelope, gp120.

Antisera to recombinant human immunodeficiency virus (HIV) proteins containing the entire envelope, gp160, or the central portion of the envelope, PB1, can inhibit fusion of virally infected cells in culture. This fusion inhibition is HIV-variant specific--that is, anti-gp160-IIIB inhibits fusion of isolate HTLV-IIIB-infected cells but not of isolate HTLV-IIIRF-infected cells. Both anti-gp160 and anti-PB1 are completely blocked in fusion inhibition activity by the addition of PB1 protein. A 24-amino acid peptide (RP135, amino acids 307-330) completely blocks fusion inhibition activity of both antisera and also blocks the activity of serum from a chimpanzee infected with HTLV-IIIB. Thus, the principal epitope that elicits fusion-inhibiting antibodies is located in the central portion of gp120.

Humoral immune response to the entire human immunodeficiency virus envelope glycoprotein made in insect cells.

The human immunodeficiency virus envelope gene was expressed in insect cells by using a Baculovirus expression vector. The protein has an apparent molecular mass of 160 kDa, appears on the surface of infected insect cells, and does not appear to be cleaved to glycoproteins gp120 and gp41. Goats immunized with the 160-kDa protein have high titers of antibody that neutralizes virus infection as measured by viral gene expression or cell cytolysis. In addition, immune sera can block fusion of human immunodeficiency virus-infected cells in culture. Both neutralization and fusion-blocking activities are bound to and eluted from immobilized gp120.

HTLV-III/LAV-neutralizing antibodies to an E. coli-produced fragment of the virus envelope.

Immunization with either an Escherichia coli recombinant segment of the human T-cell lymphotropic virus (HTLV-III/LAV) envelope protein (gp 120) or with deglycosylated gp 120 envelope protein produced antibodies that neutralize HTLV-III/LAV infection in vitro. Virus neutralization titers of these antisera were equivalent to those obtained with purified native gp120 as immunogen. This localizes at least one class of neutralizing epitopes to the carboxyl-terminal half of the molecule. In addition, native gp120 prevented HTLV-III/LAV--mediated cell fusion, whereas the recombinant gp120 fragment did not. This shows that although glycosylation is not required for induction of neutralizing antibodies, it may be important for interaction with CD4, the virus receptor. A segment of the HTLV-III/LAV envelope produced in E. coli may be an important ingredient of a vaccine for acquired immune deficiency syndrome.

Isolation of point mutations in bacteriophage Mu attachment regions cloned in a lambda::mini-Mu phage.

Twenty-one derivatives of a lambda::mini-Mu phage containing point mutations in the Mu attachment regions were isolated after mutD mutagenesis and selection for relief from Mu-specific replicative interference of lambda growth. DNA sequence analysis revealed that the single left-end mutant had suffered a T----C transition at position 1 of the Mu sequence, while the remaining 20 right-end mutants contained single base-pair insertions or deletions within the terminal 19 base pairs. A genetic assay showed that the right-end mutations revealed by sequencing were necessary for relief of the replicative inhibition of lambda growth. The properties of these mutants suggest that the terminal 2-base-pair and subterminal 8-base-pair inverted repeats are important for Mu-specific replicative transposition.

Multiple biological activities of human recombinant interleukin 1.

Complementary DNA coding for human monocyte interleukin 1 (IL-1), pI 7 form, was expressed in Escherichia coli. During purification, IL-1 activity on murine T cells was associated with the recombinant protein. Homogeneous human recombinant IL-1 (hrIL-1) was tested in several assays to demonstrate the immunological and inflammatory properties attributed to this molecule. hrIL-1 induced proliferative responses in a cloned murine T cell in the presence of suboptimal concentrations of mitogen, whereas no effect was observed with hrIL-1 alone. At concentrations of 0.05 ng/ml, hrIL-1 doubled the response to mitogen (5 X 10(6) half maximal units/mg). Human peripheral blood T cells depleted of adherent cells underwent a blastogenic response and released interleukin 2 in the presence of hrIL-1 and mitogen. hrIL-1 was a potent inflammatory agent by its ability to induce human dermal fibroblast prostaglandin E2 production in vitro and to produce monophasic (endogenous pyrogen) fever when injected into rabbits or endotoxin-resistant mice. These studies establish that the dominant pI 7 form of recombinant human IL-1 possesses immunological and inflammatory properties and acts on the central nervous system to produce fever.

Cellular differences in the molecular mechanisms of vaccinia virus host range restriction.

The biochemistry of vaccinia virus replication in two permissive (BSC-40, L-929), and two non-permissive (CHO, MDBK) cell lines has been compared. While CHO and MDBK cells differentially allowed expression of the various stages in the vaccinia developmental programme, neither cell supported production of any infectious progeny virions.

Identification of a virus-specified protein in the nucleus of vaccinia virus-infected cells.

A new protein has been detected in the nuclei of vaccinia virus-infected cells. This protein has an apparent mol. wt. of 28000 (VP28) on SDS--polyacrylamide gels and has been detected in Triton X-100-treated nuclei of infected BSC-40, L-929 and CVC cells. Within the infected cells, VP 28 was synthesized maximally at 1 to 2 h p.i. in the cytoplasm and accumulated in the nuclei at 4 to 5 h p.i. The appearance of VP28 was not affected by cytosine arabinoside (25 microgram/ml), an inhibitor of virus DNA synthesis, or rifampicin (100 microgram/ml), an inhibitor of vaccinia assembly, but was inhibited by irradiation of the infecting virions; thus classifying it as an early vaccinia virus gene product. Nuclear--cytoplasmic mixing experiments suggested that the nuclear location of VP28 was not an artefact of the cell fractionation techniques employed. VP28 did not appear to be phosphorylated.

Vaccinia virus replication requires active participation of the host cell transcriptional apparatus.

The ability of vaccinia virus to replicate in BSC-40 monkey cells whose nuclei have been functionally inactivated was examined. Exposure of cell monolayers to ultraviolet radiation at doses that did not alter the cells' capacity to support a subsequent infection by a cytoplasmic virus (vesicular stomatitis virus) caused a reduction to less than 10% in the observed yield of infectious progeny from vaccinia virus and herpes simplex virus (type 1) infections. Similarly, replication of vaccinia virus was reduced to 5% by treatment of BCS-40 cells with alpha-amanitin (10 microgram/ml), a potent inhibitor of nuclear mRNA synthesis. In both situations, ultraviolet irradiation and alpha-amanitin treatment, early and late vaccinia viral genes were expressed at high levels, but the newly synthesized virion components were not assembled into mature infectious particles. Taken together, these data suggest that the active involvement of the host cell nuclear transcriptive system is obligatory in the vaccinia virus replicative cycle.